Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).
Thompson
Paul D
PD
Buchner
David
D
Pina
Ileana L
IL
Balady
Gary J
GJ
Williams
Mark A
MA
Marcus
Bess H
BH
Berra
Kathy
K
Blair
Steven N
SN
Costa
Fernando
F
Franklin
Barry
B
Fletcher
Gerald F
GF
Gordon
Neil F
NF
Pate
Russell R
RR
Rodriguez
Beatriz L
BL
Yancey
Antronette K
AK
Wenger
Nanette K
NK
D001161:Arteriosclerosis / Q000150:complications / Q000517:prevention & control* / Q000628:therapy*; D001794:Blood Pressure / Q000502:physiology; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control* / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015444:Exercise; D017079:Exercise Tolerance / Q000502:physiology; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D015201:Meta-Analysis as Topic; D009043:Motor Activity / Q000502:physiology; D012106:Research / Q000639:trends; D018570:Risk Assessment; D012307:Risk Factors; D040242:Risk Reduction Behavior; D016540:Smoking Cessation; D016896:Treatment Outcome; D015431:Weight Loss
D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL